Comparison of SGLT2 Inhibitors for New-Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function - PubMed
3 days ago
- #SGLT2 inhibitors
- #real-world evidence
- #diabetic nephropathy
- Study compares SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) for new-onset proteinuria risk in type 2 diabetes patients with preserved kidney function.
- Target trial emulation used health checkup and claims data (2014–2023) with inverse probability weighting for confounders and follow-up loss.
- Results: Dapagliflozin showed higher new-onset proteinuria risk (HR 1.64) vs. empagliflozin, especially in men (HR 2.34).
- Empagliflozin associated with lower proteinuria risk, highlighting need for individualized SGLT2 inhibitor selection.
- Findings require validation via randomized controlled trials.